Trial Radar
Sign in

Study record

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT07203001

RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Still´s Disease

Interventions: MAS825

Countries: United States, Canada, France, Germany, Italy, Netherlands, Spain, Turkey (Türkiye)

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

1 events · 1 snapshots

1 recorded events1 registry snapshotsTracked since Jul 13, 2026Official CT.gov history
  1. Jul 13, 2026
    New TrialNotable

    Novartis Pharmaceuticals started Phase 2 Still´s Disease trial

    Registry state after update: Recruiting · Phase 2 · 8 countries

← Back to dashboard